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Introduction
Modafinil is a relatively new drug 
typically used in patients diagnosed with 
sleep disorders including narcolepsy and 
obstructive sleep apnea. It has been 
described as a “stimulant” and can produce 
cardiac symptoms such as increased blood 
pressure, asystole, chest pain, and sinus 
tachycardia.1,2 There is relatively little data 
on the correlation between modafinil use 
and risk for coronary artery disease. 
 
Case Report 
A 37-year-old white male with a history 
of narcolepsy (on modafinil) and post-
traumatic stress disorder (on lamotrigine, 
sertraline, and temazepam) presented with a 
chief complaint of chest pain. Aspirin 
therapy was initiated immediately. 
Cardiac and lung exams were 
unremarkable with clear breath sounds and 
no murmurs, rubs, or gallops. Initial 
complete blood count (CBC) showed a 
slightly elevated white blood cell count at 
13,700 x 10E3/uL, which was attributed to 
stress reaction. B-type natriuretic peptide 
(BNP), thyroid stimulating hormone (TSH) 
and electrolytes were within normal limits. 
Initial troponin I was unremarkable and 
electrocardiogram (EKG) did not show any 
ST-segment elevation or any other changes 
when compared to previous EKG.  
Approximately eight hours after 
presentation, blood pressure reached 
197/128 mmHg and troponin I increased to 
9 ng/ml then peaked at 15 ng/ml. A 
diagnosis of non-ST elevation myocardial 
infarction (NSTEMI) was made. The patient 
was taken for cardiac catheterization, which 
revealed a 90% occlusion of the left anterior 
descending artery at the trifurcation of the 
first major septal artery. A bare metal stent 
was placed and the patient’s chest pain 
resolved.  
Aspirin was continued and a beta-
blocker, statin, and clopidogrel were started 
after the procedure per acute coronary 
syndrome (ACS) protocol. The patient 
remained stable and was discharged the 
following day and was advised not to take 
modafinil.  
 
Discussion 
Modafinil is the first new psycho-
stimulant medication for narcolepsy in 20 
years. It has become popular recently due to 
its lower abuse potential and is used 
frequently in the military for soldiers 
experiencing excessive fatigue. Although 
the exact mechanism of action is poorly 
understood, it most likely acts as an agonist 
on the central alpha-1 adrenergic system or 
dopamine system producing stimulation-like 
effects on the central nervous system (CNS) 
and vasospasm and tachycardia.2,3  
Potential cardiac side effects include 
palpitations, chest pain, ischemic EkG 
changes, and dyspnea.1,2 There is a limited 
amount of literature linking the use of 
modafinil to coronary artery disease (CAD).  
However, there is a fair amount of evidence 
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that modafinil should be used with caution 
in patients with pre-existing heart conditions 
such as left ventricular hypertrophy and a 
history of myocardial infarction.4 
The prevalence of CAD in younger 
patients is difficult to establish because it is 
typically a silent process. In an autopsy 
study6 involving 760 patients aged 15 to 34 
who were victims of accidents, suicides, and 
homicides, advanced coronary atheromata 
were seen in two percent of men aged 15 to 
19, but no women. An advanced lesion was 
present in 20 and 8 percent of men and 
women aged 30 to 34, respectively, while 19 
and 8 percent, respectively, had a 40 percent 
or greater stenosis of the left anterior 
descending artery.7 
There are limited data on the frequency 
of myocardial infarction in younger, 
healthier patients with few to no risk factors. 
One study showed that, although serum 
lipids have a great role in ischemic heart 
disease, half of patients with acute 
myocardial infarction had normal lipid 
profile.8,9 Lastly, a study on known cases of 
ischemic heart disease did not show a 
combination of risk factors such as 
hyperlipidemia, hypertension, diabetes, and 
smoking. Fifteen percent of men, 19% of 
women, and more than half of all patients 
had only one classic risk factor.10,11  
Conversely, our patient was a young, 
non-diabetic, healthy male with no family 
history of CAD. He did not have 
hypercholesterolemia or metabolic syn-
drome, did not smoke, use cocaine, or other 
illicit drugs, and should not have been at risk 
for myocardial infarction. However, he was 
taking modafinil for narcolepsy for 
approximately 20 months and we believe 
this drug could have contributed directly to 
his in-hospital hypertension, CAD, and 
ultimate myocardial infarction. Another 
consideration was that modafinil indirectly 
caused his CAD as a result of his in-hospital 
hypertension. For these reasons, modafinil 
was discontinued upon admission and after 
discharge for secondary prevention.   
 
Conclusion 
Our patient was young and had minimal 
risk factors predisposing him to CAD. It is 
unclear whether the patient’s long-term use 
of modafinil contributed to his course and 
need for intervention. Further prospective 
and/or retrospective studies of patients with 
long-term usage of modafinil may be 
beneficial to define the advantages and 
disadvantages of this drug better. Also, 
further genetic studies may help our 
understanding of why certain exposures 
correlate more strongly with CAD in some 
patients compared to others. Our case 
demonstrated that modafinil may play a role 
in the CAD spectrum and that clinicians 
should keep this in mind when prescribing 
this drug.  
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